Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 31,200 shares, a drop of 28.9% from the February 13th total of 43,900 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average daily volume of 18,400 shares, the days-to-cover ratio is presently 1.7 days.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Evoke Pharma Stock Down 10.2 %

Shares of EVOK stock traded down $0.39 on Monday, hitting $3.43. The stock had a trading volume of 48,202 shares, compared to its average volume of 119,644. The business has a 50 day moving average price of $4.53 and a 200 day moving average price of $4.71. The company has a market cap of $5.10 million, a PE ratio of -0.31 and a beta of 0.12. Evoke Pharma has a one year low of $3.33 and a one year high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.24). The firm had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evoke Pharma in a report on Wednesday, March 12th. They issued a “sell” rating for the company.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.